Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155100 | 0.85 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL9446187 | 0.85 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL10121263 | 0.83 | GABRA1 (0.38) | SIGMAR1 | |
| SCHEMBL15014089 | 0.83 | S1PR1 (0.44) | SIGMAR1 | |
| SCHEMBL28106766 | 0.82 | NPC1 (0.44) | SIGMAR1 | |
| SCHEMBL19009082 | 0.82 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL11732115 | 0.81 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL22388176 | 0.80 | OPRM1 (0.46) | SIGMAR1 | |
| SCHEMBL11787169 | 0.80 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL129446 | 0.79 | SIGMAR1 (0.51) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-03-25 | — | — | US | disclosed |
| US-10208000-B2 | Eis inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170174639-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-06-22 | — | — | US | disclosed |
| US-20170174639-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-06-22 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174639-A1 | EIS INHIBITORS | ABCC1, ATP5ME, ABCG2 | SIGMAR1 3243/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | SIGMAR1 857/4885 |
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ATM, MAP3K15, MAP3K3 | SIGMAR1 4571/4885 |
| US-10208000-B2 | Eis inhibitors | ABCC1, ATP5ME, ABCG2 | SIGMAR1 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.